A Phase 3, randomized, active-comparator controlled clinical trial to study the contraceptive efficacy and safety of the MK-8342B (etonogestrel + 17β-estradiol) vaginal ring and the levonorgestrel-ethinylestradiol (LNG-EE) 150/30 µg combined oral contraceptive (COC) in healthy women 18 years of age and older, at risk for pregnancy.

Trial Profile

A Phase 3, randomized, active-comparator controlled clinical trial to study the contraceptive efficacy and safety of the MK-8342B (etonogestrel + 17β-estradiol) vaginal ring and the levonorgestrel-ethinylestradiol (LNG-EE) 150/30 µg combined oral contraceptive (COC) in healthy women 18 years of age and older, at risk for pregnancy.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Estradiol/etonogestrel (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Pregnancy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Jan 2017 This trial was discontinued in Germany (end date: 2016-10-06), according to European Clinical Trials Database.
    • 25 Nov 2016 This trial was discontinued in Poland (end date: 2016-10-06), according to European Clinical Trials Database.
    • 21 Nov 2016 This trial was completed Netherlands (end date: 2016-10-06), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top